Table 2.
All subjects (N=156) | Statin alone (n=89) | Statin + ERN (n=67) | P-value for between-group differences† | ||||
---|---|---|---|---|---|---|---|
|
|
|
|||||
Variable | Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | |
| |||||||
Mean lumen area, mm2 | 43 ± 15 | 44 ± 16 | 43 ± 16 | 43 ± 16 | 43 ± 15 | 44 ± 15 | 0.85 |
Mean wall area, mm2 | 30 ± 8 | 31 ± 8* | 30 ± 8 | 31 ± 8* | 30 ± 8 | 31 ± 8* | 0.68 |
Mean outer wall area, mm2 | 73 ± 20 | 74 ± 20* | 73 ± 21 | 74 ± 21* | 73 ± 19 | 75 ± 19* | 0.51 |
Lipid core volume, mm3 | 31 (17 – 71) | 27 (14 – 60) | 29 (16 – 53) | 26 (15 – 50) | 32 (18 – 98) | 32 (15 – 98) | 0.50 |
Lipid core, % | 7 (4 – 12) | 6 (3 – 11)* | 6 (4 – 11) | 5 (3 – 9)* | 9 (5 – 16) | 7 (4 – 19) | 0.44 |
ERN: extended-release niacin. Values are mean ± standard deviation or median (inter-quartile range) unless otherwise specified;
: p<0.05 by Wilcoxon signed-rank test comparing baseline and follow-up measurements;
Wilcoxon rank-sum test comparing annualized changes from baseline to follow-up between treatment groups.